Want to see HK:0239 full AI Analyst Report?
Top Page
Pak Fah Yeow International Limited
(0239)
Select Model
Select Model
Rating:82Outperform
Price Target:
HK$3.00
â–²(26.05% Upside)
Action:Reiterated
Date:08/04/26
The score is driven primarily by strong financial performance (high profitability, very low leverage, and solid recent cash generation) and supportive valuation (low P/E and high dividend yield). Technical indicators are moderately positive but not strongly trending, which tempers the overall rating.
Positive Factors
Strong Profitability
Sustained high profitability across recent years indicates a resilient branded consumer-health business with strong earnings conversion. This provides internal funding capacity and can support marketing, product maintenance and distribution investment over the next several quarters.
Negative Factors
Revenue Volatility
Uneven top-line performance makes the earnings base less predictable and may reflect sensitivity to product demand, geographic mix or distribution volumes. Persistent revenue volatility could limit operating leverage and make future margin strength harder to sustain.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Profitability
Sustained high profitability across recent years indicates a resilient branded consumer-health business with strong earnings conversion. This provides internal funding capacity and can support marketing, product maintenance and distribution investment over the next several quarters.
Read all positive factors
Pak Fah Yeow International Limited (0239) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$779.10M
Dividend Yield7.4%
Average Volume (3M)48.37K
Price to Earnings (P/E)7.8
Beta (1Y)-0.15
Revenue Growth10.63%
EPS Growth39.44%
CountryHK
Employees100
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.30
Shares Outstanding311,640,000
10 Day Avg. Volume101,100
30 Day Avg. Volume48,366
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)1.02
Price to Sales (P/S)3.45
P/FCF Ratio6.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pak Fah Yeow International Limited Business Overview & Revenue Model
Company Description
Pak Fah Yeow International Limited, operating with its subsidiaries, specializes in the production, promotion, and distribution of healthcare goods under the Hoe Hin brand. Its market reach spans the People's Republic of China, Hong Kong, Macau, S...
How the Company Makes Money
The company primarily makes money by selling Pak Fah Yeow branded medicated oil products and related consumer healthcare items. Revenue is generated through (1) product sales into distribution networks (e.g., wholesalers, pharmacies, retailers, an...
Pak Fah Yeow International Limited Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
83
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 213.88M | 236.91M | 259.31M | 147.20M | 139.82M |
| Gross Profit | 133.14M | 203.20M | 167.59M | 74.06M | 68.71M |
| EBITDA | 115.35M | 105.73M | 136.81M | 45.90M | 54.67M |
| Net Income | 91.35M | 78.63M | 105.04M | 29.95M | 38.19M |
Balance Sheet | |||||
| Total Assets | 828.37M | 843.35M | 907.47M | 823.14M | 837.75M |
| Cash, Cash Equivalents and Short-Term Investments | 344.54M | 290.02M | 277.61M | 180.34M | 178.28M |
| Total Debt | 6.87M | 4.20M | 4.74M | 5.50M | 16.21M |
| Total Liabilities | 105.63M | 111.45M | 142.28M | 115.91M | 130.03M |
| Stockholders Equity | 722.75M | 731.91M | 765.18M | 707.23M | 707.72M |
Cash Flow | |||||
| Free Cash Flow | 112.33M | 78.02M | 144.84M | 39.76M | 69.54M |
| Operating Cash Flow | 112.77M | 78.96M | 147.90M | 39.92M | 70.36M |
| Investing Cash Flow | -63.29M | -3.19M | 16.65M | -6.67M | -565.00K |
| Financing Cash Flow | -57.67M | -67.54M | -48.96M | -33.91M | -22.41M |
Pak Fah Yeow International Limited Technical Analysis
Positive
2.38
Price Trends
2.40
Positive
2.37
Positive
2.33
Positive
Market Momentum
0.05
Positive
53.60
Neutral
29.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0239, the sentiment is Positive. The current price of 2.38 is below the 20-day moving average (MA) of 2.49, below the 50-day MA of 2.40, and above the 200-day MA of 2.33, indicating a bullish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 53.60 is Neutral, neither overbought nor oversold. The STOCH value of 29.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0239.
Pak Fah Yeow International Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | HK$779.10M | 7.81 | 13.59% | 7.40% | 10.63% | 39.44% | |
75 Outperform | HK$1.48B | 5.52 | 6.78% | 6.36% | 6.55% | 36.62% | |
74 Outperform | HK$1.55B | 7.56 | 18.70% | 9.45% | 6.69% | 2.45% | |
70 Outperform | HK$2.00B | 6.95 | 13.26% | 8.91% | -0.47% | -0.40% | |
53 Neutral | HK$6.77B | -5.57 | -4.98% | 0.26% | -15.80% | -298.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$339.89M | 84.72 | 0.34% | 84.69% | -8.30% | -44.44% |
* Healthcare Sector Average
HK:0239
Pak Fah Yeow International Limited
2.50
0.19
8.13%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.35
-0.83
-38.02%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.31
-0.04
-12.86%
HK:2161
JBM (Healthcare) Ltd.
1.89
-0.93
-32.98%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
0.99
-0.19
-15.88%
HK:2633
Jacobson Pharma Corporation Limited
1.05
-0.35
-25.00%
Pak Fah Yeow International Limited Corporate Events
Pak Fah Yeow boosts interim profit and dividends on healthcare growth
Aug 20, 2026
Pak Fah Yeow International Limited reported interim results for the six months ended 30 June 2026 showing a 6.7% year-on-year increase in revenue to HK$101.0 million and a 3.7% rise in underlying recurring profit, driven mainly by stronger sales f...
Pak Fah Yeow Declares Interim and Special Dividends for 2026
Aug 20, 2026
Pak Fah Yeow International Limited, incorporated in Bermuda and listed on the Hong Kong Stock Exchange, operates in the consumer healthcare sector with a focus on medicated oils and related wellness products. The board is led by Chairman Gan Wee S...
Pak Fah Yeow Declares Interim Dividend for First Half of 2026
Aug 20, 2026
Pak Fah Yeow International Limited, a Hong Kong‑listed healthcare and consumer products company, derives its business from the regional market, with shares quoted on the Main Board under stock code 00239. The board comprises a mix of executi...
Pak Fah Yeow Declares Special Interim Dividend for First Half of 2026
Aug 20, 2026
Pak Fah Yeow International Limited, a Hong Kong-listed consumer healthcare company known for its medicated oils and topical remedies, generates steady cash flow from its established brands in regional markets. Its defensively positioned business a...
Pak Fah Yeow Sets August Board Meeting to Review Interim Results and Dividend
Aug 10, 2026
Pak Fah Yeow International Limited has scheduled a board meeting for 20 August 2026 to review and approve the interim results of the company and its subsidiaries for the six months ended 30 June 2026. The board will also consider the declaration o...
Pak Fah Yeow flags higher interim profit on revenue growth and lower property losses
Jul 31, 2026
Pak Fah Yeow International has issued a positive profit alert, indicating that consolidated net profit attributable to shareholders for the six months ended 30 June 2026 is expected to rise to about HK$47.4 million, up from HK$39.7 million a year ...
Pak Fah Yeow Owner Restructures Hexagan Stake in Family Succession Move
Jun 30, 2026
Pak Fah Yeow International Limited has announced a change in the shareholding structure of its substantial shareholder Hexagan Enterprises Limited as part of a family succession plan. The move affects ownership of Hexagan itself but leaves the com...
Pak Fah Yeow Wins Strong Shareholder Backing for Dividends, Mandates and Bye-law Changes
Jun 2, 2026
Shareholders of Pak Fah Yeow International Limited overwhelmingly approved all resolutions at the 2 June 2026 annual general meeting, including the 2025 financial statements and the payment of both a final dividend of HK3.8 cents per share and a s...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.